July 6, 2018 6:03pm

The iShares Nasdaq Biotechnology ETF (IBB) surged 3.88% boosted by Biogen (BIIB) shares rising 19.63% (with a positive aftermarket indication of +$0.92 or +0.26%) after announcing positive results from a study on a drug aimed at treating early Alzheimer’s disease.

 

The issue is the DRAMA of the incline and is another “Icarus” storyline POSSIBLE?

 

Pre-open indications: 0 HIT and 4 MISS

 

It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

Want to know WHY, subscribe!

 

Henry’omics:

 

The OVERBOUGHT are glaring … the targets on their back shines brightly…

Know what you know, think what you think … stick to your beliefs, follow your honed instincts – they don’t lie to you!

  • If you’re a “watcher” or been on a “stake-out”; it’s not always apparent in the time-frame anticipated but, it usually happens …

I just like being early to the BUY/SELL window

  • Reiterating, the issue is the DRAMA of the incline and another “Icarus” storyline POSSIBLE?

 

Out and about:  “I am still agitating trouble about gene editing equity’ pricing.” Not a huge fan but, script rules some truth … https://scroll.in/video/885089/watch-john-oliver-tells-us-why-we-should-not-be-afraid-of-gene-editing-should-we-believe-him “

I further believe and reiterate … “Gene editing stocks are again getting lofty after feeling little pain and are trading magnets with yet to be proven platform “integrity” – there is still a “stain” of “a disturbing link between the gene-editing technology and cancer”.  What has gene editing shown us to date – I haven’t seen or have heard ground breaking RESULTS, just a “could’a” or might be platform.”

Speculation at its best: too many trades just “playing through” …

  • CRISPR Therapeutics (CRSP) had (Thursday) closed up +0.48 to $61.74, opened at $61.62 and closed at $62.88 (+$1.14) in a day’s range of $61.00 to $63.85 – a bit of slippage;
  • Intellia Therapeutics (NTLA) had (Thursday) closed up +$0.84 to $29.57, opened at $29.92 and closed at $31.44 (+$1.78) in a day’s range of $29.68 to $35.99 – another with slippage;
  • Editas Medicine (EDIT) had (Thursday) closed up +0.01 to $36.83, opened at $36.909 and closed at $37.94 (+$1.11) in a day’s range of $36.90 to $38.30 – another with slippage;

 

From the pre-open newsletter titled, “zip-a-dee-doo-dah; then you wish upon an upside session, makes a difference who you invest in. Today, your dreams might have issues if trade issues come due.”

I also stated, “The challenge of today’s session will be anticipating the forthcoming Monday;  IF momentum is constricted will it weigh heavily on sentiment and then we won’t be so … zip-a-dee.”

 

Of the 45 companies covered on Friday; 8 downside equities finished in a range of -$0.0072 (KOOL) to -$0.42 (CLBS) while the 35 upside equities oscillated from +$0.01 (PSTI) to $7.75 (BLUE) with 2 flat close.

 

MY working trend (5 largest) lines:

… The greatest volume to the downside:  MDXG, VSTM, KOOL, BOLD and BCLI

… Upside volume was weighted to:  SGMO, XON, BLUE, BLCM and NTLA

… Biggest $ downside:  CLBS (-$0.42), MDXG (-$0.41), BCLI (-$0.14), AGTC (-$0.13) and HSGX (-$0.06)

… Best moves to the $ upside: BLUE (+$7.75), RARE (+$4.47), ONCE (+$3.93), SLDB (+$3.31) and ALNY (+$2.98)

… Flats:  BSTG and RENE.L

 

The weekly count - decliners versus gainers – new month:

……. look at the differences in decliners:

  • Friday’s decliners ranged from -0.05% <BOLD -$0.02 > to -10.9% < MDXG -$0.41> in 8 equities;
  • Thursday’s decliners ranged from -0.18% <BLFS -$0.03 > to -5.51% < MDXG -$0.22> in x equities;
  • Wednesday was a holiday
  • Tuesday’s decliners ranged from -0.14% <RARE -$0.11 > to -5.97% <BSTG -$0.27 > in 9 equities;
  • Monday’s decliners ranged from -0.20% <AXGN -$0.10> to -38.5% <MDXG -$2.46> in 15 equities;

Versus

… Look at the percentage’s (%) and spreads …

  • Friday’s gainers ranged from +0.31% <CLLS +$0.09 > to +8.5% < SLDB +$3.31> in 35 equities;
  • Thursday’s gainers ranged from +0.03% <EDIT +$0.01> to +9.46% < KOOL +$0.0038> in 23 equities;
  • Wednesday was a holiday
  • Tuesday’s gainers ranged from +0.55% < ALNY +$0.54> to +11.41% <BLFS +$1.71 > in 33 equities;
  • Monday’s gainers ranged from +0.04% <AST +$0.00> to +31.38% <BLFS +$3.58 > in 27 equities;

 

Daily analytics and metrics:

  • The Dow jumped 99.74 points to 24,456.48.
  • The S&P 500 closed 0.8% higher at 2,759.82, with health care rising 1.5%.
  • The NASDAQ climbed 1.3% to 7,688.39.

 

The advance/decline line scenario of 45 covered companies:   

  • The open was positive with an A/DL of 33/11 and 1 flat;
  • The mid-day was positive with an A/DL of 35/7 and 3 flats;
  • The close was positive with an A/DL of 35/8 and 2 flat;

 

Pre-open indications: 0 hit and 4 miss

  • bluebird bio (BLUE) closed up +$7.75 – miss;
  • CRISPR Therapeutics (CRSP) closed up +$1.14 – miss;
  • Intellia (NTLA) closed up +$1.78 – miss;
  • Editas Medicine (EDIT) closed up +$1.11 – miss;

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

  • Friday traded at 13.37, down -10.69%
  • Thursday traded at 15.15, down -6.13%
  • Wednesday was a holiday;
  • Tuesday traded at 16.14, up +3.46%
  • Monday traded at 15.6, down -3.05%

 

The iShares Russell 2000 (IWM) closed:

  • Friday was up +0.85%;
  • Thursday was up +1.15%;
  • Wednesday was a holiday;
  • Tuesday was up +0.40%;
  • Monday was up +0.68%;

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Friday was up +3.78%
  • Thursday was up +1.26%
  • Wednesday was a holiday;   
  • Tuesday was down -0.09%
  • Monday was up +0.79%

 

JULY sessions:

  • Friday closed POSITIVE with 8 decliners, 35 advancers and 2flat;
  • Thursday closed POSITIVE with 18 decliners, 23 advancers and 4 flat;
  • Wednesday was a holiday;
  • Tuesday closed POSITIVE with 9 decliners, 33 advancers and 3 flat;
  • Monday closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.